Regulatory Story
Go to market news section View chart   Print
Shire plc  -  SHP   

Transaction in Own Shares

Released 07:00 24-Jul-2013

Transaction in Own Shares

Transaction in Own Shares

July 24, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that, in accordance with the authority granted by shareholders at the Company's
Annual General Meeting on April 30, 2013, it purchased 7,301 of its ordinary
shares of 5 pence each ("Ordinary Shares") on July 23, 2013 through both direct
purchases of Ordinary Shares, and through the purchase of Ordinary Shares
underlying ADRs. The highest and lowest price paid for the directly acquired
Ordinary Shares was 2237.00 pence per share and 2229.00 pence per share
respectively, and for those Ordinary Shares acquired though the purchase of
ADRs was 3439.00 cents per share and 3427.00 cents per share respectively.

The purchased shares will be held as treasury shares. Following the above
purchase, the Company holds 9,567,253 Ordinary Shares as treasury shares and
has 553,291,382 Ordinary Shares in issue (excluding treasury shares).

The purchases were made by an independent third party which makes its trading
decisions independently of, and uninfluenced by, the Company. The independence
of the third party enables the Company to continue to purchase Ordinary Shares
(including Ordinary Shares underlying ADRs) during close periods and other
prohibited periods, should they arise. The third party has been appointed by
the Company to make purchases to December 31, 2013.

For further information please contact:

Investor Relations                                                             
Eric Rojas                         +1 781 482 0999   
Sarah Elton-Farr               +44 1256 894157   


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing treatments
for symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release                                     


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Transaction in Own Shares - RNS